You're using an outdated browser. This website will not display correctly and some features will not work.
Learn more about the browsers we support for a faster and safer online experience.


ontario regulation 54/06

made under the

drug interchangeability and dispensing fee act

Made: March 1, 2006
Filed: March 3, 2006
Published on e-Laws: March 6, 2006
Printed in The Ontario Gazette: March 18, 2006

Amending Reg. 935 of R.R.O. 1990


1. (1) The definition of “Formulary” in subsection 1 (1) of  Regulation 935 of the Revised Regulations of Ontario, 1990 is revoked and the following substituted:

“Formulary” means the Ministry of Health and Long-Term Care publication titled “Drug Benefit Formulary/Comparative Drug Index” (No. 39) dated September 27, 2005, and includes the following amendments to the publication:

1. Amendments dated January 12, 2006.

2. Amendments dated April 19, 2006;

(2) Subsection 1 (1.1) of the Regulation is revoked. 

(3) Section 1 of the Regulation is amended by adding the following subsection:

(1.3) For the purposes of this Regulation, item 231 of Part III of the Formulary shall be read as follows:



2.5 mg Tab






Femara (Letrozole)




Reason for Use Code

Clinical Criteria



For the treatment of metastatic breast cancer in hormone receptor positive postmenopausal women. LU Authorization Period: Indefinite.



For the treatment of hormone receptor positive early breast cancer in postmenopausal women who have received 5 years of adjuvant tamoxifen therapy. LU Authorization Period: 5 Years.

2. This Regulation comes into force on April 19, 2006.